Table 4 Analysis for potential prognostic factors.
Status after a median follow-up of 127 months N (%) | |||
|---|---|---|---|
Censor | Uncensor | p | |
Median age at first diagnosis: | |||
− <58 years | 29 (48) | 2 (3) | 0.001 |
− ≥58 years | 13 (21) | 17 (28) | |
Sex: | |||
− Male | 23 (38) | 7 (11) | >0.999 |
− Female | 23 (38) | 8 (13) | |
Cytogenetics (available for 27 patients): | |||
− Normal | 15 (56) | 2 (7) | 0.326 |
− Abnormal | 7 (20) | 3 (11) | |
MPN diagnosis: | |||
− PV, ET, MPN-U | 39 (64) | 11 (18) | 0.439 |
− MF | 4 (7) | 7 (11) | |
Driver MPN mutations (available for 59 patients): | |||
− JAK2 | 37 (63) | 11 (19) | >0.999 |
− CALR, MPL | 8 (13) | 3 (5) | |
Additional mutations (available for 43 patients): | |||
− No | 20 (46) | 12 (28) | 0.129 |
− Yes | 10 (23) | 1 (3) | |
BCR::ABL1 transcript (available for 49 patients): | |||
− p190 | 4 (8) | 3 (6) | 0.05 |
− p210 | 34 (69) | 8 (17) | |
ELTS score at diagnosis (available for 49 patients): | |||
− Low | 14 (29) | 2 (5) | 0.227 |
− Intermediate | 10 (20) | 6 (12) | |
− High | 11 (22) | 6 (12) | |
MPN treatment: | |||
− W&W/venesection | 10 (16) | 1 (2) | 0.264 |
− At least 1 therapy | 36 (59) | 14 (23) | |
CML treatment (TKI): | |||
− 1 line | 28 (46) | 12 (20) | 0.344 |
− 2 lines | 8 (13) | 2 (3) | |
− 3 lines | 10 (16) | 1 (2) | |
